Dr. Rosenblatt Named Director of the Margaret M. Dyson Vision Research Institute

On behalf of the Department of Ophthalmology, Professor and Chairman Donald J. D'Amico, MD is pleased to announce the appointment of Mark I. Rosenblatt, MD, PhD as Director of the Margaret M. Dyson Vision Research Institute at Weill Cornell Medical College. The Dyson Institute is one of the top 20 NIH funded ophthalmic research institutes in the United States.

Dr. Rosenblatt received his clinical and research degrees from the University of Miami Miller School of Medicine and then completed his ophthalmology residency training and a combined clinical-research fellowship at the Harvard University affiliated Massachusetts Eye and Ear Infirmary and Schepens Eye Research Institute. He joined the Department of Ophthalmology in 2008 as an Assistant Professor in the Cornea and Refractive Surgery service and Principal Investigator in the Dyson Institute.

Dr. Rosenblatt is an internationally recognized clinician-scientist with research and clinical programs focusing on ocular regenerative medicine. His laboratory is investigating the molecular underpinnings of corneal repair as well as the use of novel biomaterials for the tissue engineering of corneal replacements. He is currently supported by National Eye Institute sponsored grants, a Tri-Institutional Stem Cell Initiative Grant, and is a recipient of the prestigious Research to Prevent Blindness Career Development Award.

The Margaret M. Dyson Vision Research Institute was established in 1989 to provide support for basic scientists unraveling mechanisms of eye disease. Under Dr. Rosenblatt's direction the Dyson Institute will undergo an expansion with newly renovated lab space and the recruitment of additional talented scientists and clinician-scientists. Building on the continuing success of the ongoing basic eye research and expertise in the laboratory, Dr. Rosenblatt will bring an additional emphasis on translating our rapidly growing understanding of the mechanisms of eye disease into new means for the diagnosis and treatment of patients with potentially blinding conditions.

Top of page